Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q4 FY21 results · Jan–Mar 2021
Ajanta Pharma reported revenue from operations of ₹756.84 crore (up 11.0% from Q4 FY20) and net profit of ₹159.26 crore (up 23.3% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 756.84 | 681.96 | +11.0% | 748.74 | +1.1% |
| Other income | 2.53 | 56.69 | −95.5% | 5.48 | −53.8% |
| Total income | 759.37 | 738.65 | +2.8% | 754.22 | +0.7% |
| Profit before tax | 228.78 | 175.86 | +30.1% | 215.47 | +6.2% |
| Net profit for the period | 159.26 | 129.16 | +23.3% | 176.63 | −9.8% |
| EPS, basic (₹) | 18.40 | 14.80 | +24.3% | 20.41 | −9.8% |
| Net margin (%) | 21.0 | 18.9 | 23.6 |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 748.07 | 560.68 | +33.4% | 733.16 | +2.0% |
| Other income | 1.33 | 54.10 | −97.5% | 2.90 | −54.1% |
| Total income | 749.40 | 614.78 | +21.9% | 736.06 | +1.8% |
| Profit before tax | 216.75 | 129.62 | +67.2% | 218.34 | −0.7% |
| Net profit for the period | 154.78 | 88.51 | +74.9% | 179.95 | −14.0% |
| EPS, basic (₹) | 17.89 | 10.14 | +76.4% | 20.80 | −14.0% |
| Net margin (%) | 20.7 | 15.8 | 24.5 |
Consolidated
- Filed with BSE
- 03 May 2021, 13:26 IST
- Board meeting
- 30 Apr 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 03 May 2021, 13:26 IST
- Board meeting
- 30 Apr 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE